Our Vision and Mission
We are a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world.
Our mission is to harness transformative science and global partnerships to bring innovative vaccines to populations worldwide.
LEARN MORE>>
Technology
We leverage the Trimer-Tag technology platform and our in-house manufacturing and commercial capabilities to develop innovative vaccines.
LEARN MORE>>
Pipeline
We have a diverse pipeline of candidates with the potential to make a meaningful difference in improving health around the world.
LEARN MORE>>Areas of Focus
Vaccines
Other
Diseases
Latest News
Oct 20, 2025
Clover Appoints Nicholas Jackson, Ph.D., as President of Global R&D and Alliances
Oct 14, 2025
Clover Announces Positive Phase I Clinical Data for RSV-hMPV-PIV3 Combination Vaccines and for RSV Re-Vaccination in Older Adults
Jun 17, 2025
Clover Initiates Phase I Clinical Trial for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates
Mar 24, 2025
Clover Announces U.S. IND Clearance and Initiation of Revaccination Clinical Study for RSV Vaccine Candidate SCB-1019
